Search for: [Abstract = "s the search for pharmacologically active new vanadium compounds in the form of their complexes, which have several advantages over organic compounds. The aim of the study was to evaluate the pharmacological activity of newly developed and synthesized vanadium complexes by studying their effects on metabolic processes related to various disruptions in glucose and lipid metabolism. This evaluation considered diverse mechanisms and cell models that represent target tissues for antidiabetic effects. The preliminary screening involved the examination of 110 newly synthesized vanadium complexes from various structural groups, which have obtained international patent protection. 93% of the tested complexes showed higher activity in stimulating glucose uptake by C2C12 myocytes compared to bis\(maltolato\)oxovanadium\(IV\) \(BMOV\) and its methyl analogue bis\(ethylmaltolato\)\-oxovanadium\(IV\) \(BEOV\), which have demonstrated antidiabetic efficacy in clinical studies. Approximately 50% of the complexes showed better efficiency than BMOV in lipid accumulation by 3T3\-L1 adipocytes and insulin secretion by RINm5F pancreatic beta cells. Numerous complexes exhibited greater activity than clinically confirmed antidiabetic compounds such as glibenclamide, rosiglitazone, or metformin, without cytotoxic effects. Vanadium complexes with high pharmacological activity were identified, exhibi"]

Number of results: 1